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Background: Although distinct patterns of homeobox (HOX) gene expression have been described in defined
cytogenetic and molecular subsets of patients with acute myeloid leukemia (AML), it is unknown whether these
patterns are the direct result of transcriptional alterations or rather represent the differentiation stage of the
leukemic cell.
Method: To address this question, we used qPCR to analyze mRNA expression of HOXA and HOXB genes in bone
marrow (BM) samples of 46 patients with AML and sorted subpopulations of healthy BM cells. These various stages
of myeloid differentiation represent matched counterparts of morphological subgroups of AML. To further study
the transcriptional alterations of HOX genes in hematopoiesis, we also analyzed gene expression of epigenetic
modifiers in the subpopluations of healthy BM and leukemic cells.
Results: Unsupervised hierarchical clustering divided the AMLs into five clusters characterized by the presence of
prevalent molecular genetic aberrations. Notably, the impact of genotype on HOX gene expression was significantly
more pronounced than that of the differentiation stage of the blasts. This driving role of molecular aberrations was
best exemplified by the repressive effect of the PML-RARa fusion gene on HOX gene expression, regardless of the
presence of the FLT3/ITD mutation. Furthermore, HOX gene expression was positively correlated with mRNA levels of
histone demethylases (JMJD3 and UTX) and negatively correlated with gene expression of DNA methyltranferases. No
such relationships were observed in subpopulations of healthy BM cells.
Conclusion: Our results demonstrate that specific molecular genetic aberrations, rather than differentiation per se,
underlie the observed differences in HOX gene expression in AML. Moreover, the observed correlations between
epigenetic modifiers and HOX ex pression that are specific to malignant hematopoiesis, suggest their potential causal
relationships.
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The clustered homeobox (HOX) genes encode a large
family of transcription factors characterized by the pres-
ence of a highly conserved nucleotide sequence called the
homeodomain. This 61-amino-acid helix-turn-helix do-
main is responsible for the binding of HOX proteins
to their target DNA sequences. In humans, the 39 HOX
genes are organized into four genomic regions (the HOXA,
B, C and D clusters) located on four chromosomes
(chromosomes 7, 17, 12 and 2, respectively). Each cluster
consists of 9 – 11 genes arranged in the same orientation
and in paralogous groups [1,2].
HOX genes play essential roles during embryogenesis
by controlling cell fate along the anterior-posterior axis
and specifying segment identity [3-5]. The characteristic
expression of HOX genes can also be detected in various
adult tissues [6,7]. During hematopoiesis, the highest ex-
pression of HOX genes occurs in the stem and early
hematopoietic progenitor cells. During maturation, HOX
expression gradually decreases, and it is minimal in dif-
ferentiated hematopoietic cells [8,9]. The expression of
HOX genes throughout the maturation of hematopoietic
cells is tightly regulated, suggesting that disruption of
this regulation contributes to the process of malignant
transformation.
The oncogenic potential of HOX genes in leukemia has
been intensively studied for more than two decades. Sev-
eral chromosomal translocations in leukemia involve HOX
genes either directly (e.g., NUP98-HOX fusion) or via their
upstream regulators (e.g., MLL rearrangements) [10-13].
Moreover, the overexpression of certain HOX genes and
their cofactors are known as poor prognostic markers in
leukemia patients [14-16]. The overexpression of HOX
genes is believed to induce myeloproliferation, which to-
gether with additional aberrations, may lead to leukemia.
The regulation of gene expression during hematopoie-
sis is controlled by the cooperation of transcription fac-
tors and the dynamic architecture of chromatin. The
specific epigenetic landscape influences target gene ac-
cessibility. As major executors of epigenetic regulation,
chromatin-modifying enzymes mediate DNA and his-
tone modifications responsible for the unique dynamics
of chromatin observed throughout hematopoiesis. The
deregulation of this process likely contributes to the ma-
lignant transformation of hematopoietic cells.
In embryogenesis, spatio-temporal expression of HOX
genes is regulated by the trithorax-group (TrxG) and
polycomb-group (PcG) proteins. PcG genes maintain
HOX gene silencing through methylation of histone 3 ly-
sine 27 (H3K27). In contrast, TrxG genes are responsible
for maintaining previously established HOX gene expres-
sion through trimethylation of histone 3 lysine 4 (H3K4)
[8,17]. A similar effect of PcG and TrxG genes has been
proposed in the regulation of HOX gene expression inhematopoiesis as suggested by the severe defects of
hematopoietic cells that have been reported in PcG and
TrxG knock-out models [18,19]. In addition, the H3K4
demethylase LSD1 and JmjC-domain-containing H3K27
demethylases JMJD3 (KDM6B) and UTX (KDM6A) have
been shown to contribute to HOX gene regulation in
embryonic development [20,21]. LSD1 establishes an in-
active chromatin configuration by H3K4 demethylation,
whereas JMJD3 and UTX activate chromatin by demeth-
ylation of H3K27. Finally, DNA methylation has been
shown to participate in the establishment of HOX gene
expression patterns, further supporting the role of epi-
genetics in the regulation of these genes [22].
In this paper, we sought to determine whether the pat-
tern of leukemic HOX gene expression was primarily
driven by the differentiation stage of hematopoietic cells
or determined de novo during the process of malignant
transformation. To approach this question, the expres-
sion patterns of the HOX genes were correlated with the
molecular genetics and morphological characteristics of
the leukemic cells of patients with childhood acute mye-
loid leukemia (AML). To further study the regulation of
HOX gene expression, we also examined the relation-
ships of chromatin modifiers and HOX genes in normal
and malignant myelopoiesis.Methods
BM samples of healthy donors and patients with AML
Subpopulations of healthy BM representing developmen-
tal stages of hematopoiesis were sorted from the samples
of healthy volunteers or minimal residual disease (MRD)-
negative leukemia patients in long-term complete remis-
sion (Fluorescence Activated Cell Sorter (FACS) Aria, BD,
San Jose, CA, USA). The combination of surface markers
that was used to identify the particular stages of myeloid
lineage differentiation is listed in Table 1. To ensure ad-
equate analysis sensitivity, we pooled the sorted samples
of each subpopulation from five control donors and proc-
essed them as described below.
In total, 46 patients with childhood AML enrolled in
the study were diagnosed and treated from 1998 to 2010
at the Czech Pediatric Hematology Working Group cen-
ters (Additional file 1: Table S1). Following the University
Hospital Motol ethical committee's approval number
P304/12/2214 and written informed consent, mono-
nuclear cells were isolated from the diagnostic BM sam-
ples using a density gradient medium (Ficoll-Paque Plus,
GE Healthcare Life Sciences, Uppsala, Sweden) and stored
at −80°C.
RNA from both the patient samples and the healthy
donor BM subpopulations were isolated with RNeasy Mini
Kit (Qiagen, Hilden, Germany) and transcribed to cDNA
using the iScript kit (Bio-Rad, Hercules, CA, USA).
Table 1 Identification of subpopulations of healthy BM cells
Normal sorted populations of myeloid lineage Counterparts with FAB AML
Granulocyte lineage subpopulations
G1 myeloid progenitor CD117+CD15-CD11b- AML M1 AML M2
G2 promyelocyte CD117+CD15+CD11b- AML M3 AML M2
G3 promyelocyte-myelocyte CD117-CD13++CD16-
G4 myelocyte CD117-CD13dimCD16-
Monocyte lineage subpopulations
M1 myeloblast CD34+SSc++HLA DR+CD33- AML M1-M0
M2 myelo/monoblast CD34+Ssc++HLA DR+CD33+ AML M2
M3 promonocyte CD34-FSc and Ssc corresponding to monocytes CD33+CD14- AML M4 - AML M5a
M4 monocyte CD34-FSc and Ssc corresponding to monocytes CD33+CD14+ AML M5b
Main characteristics of stages of myeloid lineage differentiation – surface markers and their counterparts with morphological subtypes of AML.
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The quantification of gene expression was performed
using the iCycler iQ System (BioRad, Hercules, CA, USA).
The primer design and qPCR conditions for amplification
of the HOXA and HOXB genes in the sorted populations
(HOXA3, A4, A5, A6, A7, A9, A10, B2, B4, B5, B6, and
B7) and patient samples (HOXA1, A3, A4, A5, A6, A7,
A9, A10, A11, A13, B1, B2, B4, B5, B6, B7, B8, and B9)
as well as the chromatin modifier genes (PcG family:
EZH2 and BMI1; Trx family: MLL; DNMTs: DNMT1,
DNMT3a, and DNMT3b and histone demethylases: JMJD3,
UTX and LSD1) were performed as previously described
[14,15,20,23-25]. To normalize the gene expression levels,
we used the ABL1 gene, which is known to be stably ex-
pressed during the development of myeloid lineage cells.Mutation analysis
The mutation statuses of the NPMI, NRAS, KRAS, CEBPa,
c-KIT and FLT3 genes were determined in 12 patients for
whom material was available and who were negative for
the presence of the four major molecular aberrations
(Additional file 1: Table S1). The analysis was performed
by qualitative PCR followed by the sequencing of particu-
lar amplicons with the primers and PCR conditions as de-
scribed earlier [26-29].Statistical analysis
Data were analyzed using the statistical software packages
Prism (GraphPad, La Jolla, CA, USA), Excel (Microsoft
Corporation, Redmond, WA, USA), StatView (SAS Institute,
Cary, NC, USA) and R-project (Vienna, Austria). The
statistical significance of the differences among the sub-
groups of samples was assessed using non-parametric
tests (Mann–Whitney and Kruskal–Wallis tests with
Dunn’s multiple comparison post test). Gene expression
correlations were estimated by Spearman’s rank correlation.Unsupervised hierarchical cluster analysis (HCA), per-
formed with the Genesis software (Institute for Geno-
mics and Bioinformatics, Graz University of Technology
(IGB-TUG), Graz, Austria), was used to identify the
subgroups of samples with similar gene expression
patterns.Results
Expression patterns of HOX genes in sorted
subpopulations of healthy BM cells representing different
stages of myelopoiesis
Using FACS, we obtained eight subpopulations of normal
BM donor cells, based on characteristic surface markers,
which represent distinct stages of myeloid differentiation.
The subpopulations corresponding with particular matur-
ation stages were selected based on our expertise and pre-
viously published studies (Table 1) [30-32]. Notably, we
frequently observed the asynchronous expression of anti-
gens and the overlap of immunophenotypic maturation
stages in the leukemic blasts.
To better demonstrate the dynamics of HOX gene
expression throughout hematopoiesis, data from the
subpopulations of the two developmental lineages of
myelopoises (granulocytic and monocytic) with the par-
allel differentiation stage were pooled together. This re-
sulted in the discernment of four consecutive stages of
myeloid development (stage 1 = G1 +M1, stage 2 = G2 +
M2, stage 3 =G3 +M3 and stage 4 = G4 +M4). In accord-
ance with previously published data, the expression of
HOXA and particular HOXB (HOXB2 and HOXB4) genes
gradually decreased during myeloid maturation (Figure 1A
and Additional file 2: Figure S1). As assessed by compari-
sons on an one-to-one basis we also observed a clear posi-
tive correlation of HOX gene expression within HOXA
cluster and HOXB cluster as well as between both clusters
(Additional file 3: Figure S2).
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Figure 1 Expression levels of HOXA and HOXB genes in subpopulations of healthy BM and samples of patients with AML. A. four
consecutive stages of myeloid lineage differentiation; B. morphological subgroups of AML patients; C. subgroups of AML with typical
molecular aberrations.
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patients with childhood AML
Distinctive HOX gene expression patterns were observed
among the French-American-British classification (FAB)
AML subtypes (Kruskal-Wallis test: p < 0.0001 for the
HOXA and p = 0.0016 for the HOXB cluster; Figure 1B
and Additional file 4: Figure S3). The M3 FAB subtype
had the lowest levels of HOXA and HOXB gene expressioncompared with other FAB subtypes (see Additional file 4:
Figure S3). In contrast, AML M5 had the highest HOXA
gene expression levels, along with the largest number of
individual HOXA genes showing significant differential
expression (Additional file 4: Figure S3). Significant dif-
ferences were also found among subgroups defined ac-
cording to molecular genetics (i.e., Kruskal-Wallis test:
p < 0.0001 for the HOXA and p = 0.0001 for the HOXB
Skvarova Kramarzova et al. Journal of Hematology & Oncology  (2014) 7:94 Page 5 of 12cluster; Figure 1C and Additional file 5: Figure S4). Pa-
tients with PML-RARa fusion showed the lowest levels
of HOXA and HOXB gene expression, while those with
MLL rearrangements expressed HOXA genes at the
highest levels (the majority of individual HOX gene
comparisons revealed significant differential expres-
sion in the PML-RARa and MLL+ patients, respect-
ively). Moreover, unsupervised hierarchical clustering
based on HOX expression divided the leukemias into
five main clusters characterized by the presence or ab-
sence of prevalent gene rearrangements, i.e., PML-RARa,
RUNX1-RUNX1T1(AML1-ETO), CBFb-MYH11 and MLL
alterations (Additional file 6: Figure S5). Interestingly,
three patients from cluster 1 (i.e., those having the over-
all highest levels of HOX gene expression and absence
of these translocations) harbored a mutation in the
NPM1 gene, similar to what has been reported in adult
AML [16].
High risk (HR) patients expressed HOXA genes at sig-
nificantly higher levels compared with patients who were
assigned to the standard risk (SR) group (p < 0.0001 for
HOXA3 - A13 and p = 0.0004 for HOXA1). However, no
differences were observed in HOXB expression between
high and low risk patients. In addition, both HOXA and
HOXB gene expression were not found to be related to
the patient age or risk stratification (Additional file 7:
Figure S6; risk group stratification of childhood AML
(AML-BFM 98 and 2004): standard risk - FAB M1/M2
with Auer rods, M3, M4eo, Down sy, t(8;21), t(15;17),
inv(16), and ≤ 5% of blasts in BM at D15 (except M3);
high risk - others).
Impact of molecular aberrations on HOX gene expression
within the morphological subgroups of AML
The effects of genetic aberrations on HOX gene expres-
sion were even more apparent when analyzed within the
morphological FAB subtypes. In AML M4, the CBFb-
MYH11+ patients exhibited statistically significant levels
of lower HOX expression compared with those lacking the
rearrangement. For AML M2, the RUNX1-RUNX1T1+ pa-
tients tended to show reduced levels of HOX gene expres-
sion compared with patients without the rearrangement
(Figure 2A and 2B; p values indicated in figure legend).
Different effect of FLT3/ITD on HOX gene expression in
the presence of PML-RARa fusion gene
In adults with normal cytogenetic AML, NPMI1 mutations
are associated with high HOX expression and those leuke-
mias have a higher frequency of FLT3 mutations [33]. In
our samples, HOX gene expression in the PML-RARa+ pa-
tients remained at very low levels regardless of the
presence of FLT3/ITD mutations (FLT3/ITD+ (N = 4)
vs. FLT3/ITD- (N = 4); Figure 3A; p values indicated in
figure legend). In contrast, in the absence of a PML-RARa fusion, HOX levels were higher when FLT3 was
mutated. These results were further emphasized by the
analysis of gene expression data from a larger (N = 48)
independent cohort of FLT3/ITD+ childhood AML pa-
tients [34], which demonstrated that HOXA and HOXB
gene levels were significantly reduced in FLT3/ITD+
patients with PML-RARa (N = 12) compared to those
without the fusion gene (N = 36; Figure 3B).
HOX gene expression patterns in corresponding
differentiation stages of normal and malignant
myelopoiesis
As indicated above, we sorted the subpopulations of nor-
mal BM cells from the healthy donors according to the
specific stage of myelopoiesis. Our gating strategy enabled
a comparison of these subpopulations with the FAB sub-
types of AML patients exhibiting the similar stage of mye-
loid maturation arrest. The list of AML subtypes assigned
to particular stages of myelopoiesis is provided in Table 1.
Differential HOX gene expression patterns were identi-
fied between the normal and malignant hematopoietic
counterparts, as demonstrated by comparing AML M3
with the corresponding stage of promyelocytes (ID =G2).
These differences were particularly evident for HOXA5,
HOXA6, HOXA9, HOXA10 and HOXB4 (Figure 4). Simi-
larly, differential expression of HOXA3, HOXA4, HOXA5,
HOXA6, HOXA7, HOXA9, HOXA10, HOXB5 and HOXB6
distinguished leukemic cells of the M5a and M5b FAB
subtypes from the matched normal counterparts, repre-
sented by the sorted M3 and M4 population, respectively
(Additional file 8: Figure S7A and 7B).
Expression patterns of chromatin modifiers and their role
in HOX gene regulation
In subpopulations of healthy BM cells, we analyzed the ex-
pression of chromatin modifying genes, previously shown
to contribute to HOXA and HOXB regulation during em-
bryogenesis [21,35,36]. Based on observed expression in
the sorted subpopulations, the chromatin modifiers were
divided into three groups. The first group, “Modifiers 1”,
included genes that did not exhibit varying expression
levels during differentiation (EZH2, BMI1, MLL, LSD1
and DNMT1). The second group, “Modifiers 2”, consisted
of genes showing increased expression during hemato-
poiesis (JMJD3 and UTX). Expression levels of the third
group, “Modifiers 3” (DNMT3a and DNMT3b), showed a
decrease concomitant with differentiation, which were sta-
tistically inversely correlated with Modifiers 2 (R = −0.922;
Figure 5A). However, we did not observe a clear pattern
of corresponding HOX gene expression changes in these
cells.
In leukemic cells, the expression of Modifier 1 genes,
except for BMI1, paralleled their normal counterparts,
being largely unchanged among the morphological AML
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Figure 2 Differing HOX gene expression levels observed in FAB subtypes with respect to the presence of typical molecular
aberrations. A. CBFb-MYH11+/− patients with AML M4. Asterisks indicated statistical significance (*≤ 0.05, **≤ 0.01; additional borderline
significance: p = 0.0679 for HOXA7, HOXA10 and HOXB9, p = 0.0732 for HOXA13); B. RUNX1-RUNX1T1+/− patients with AML M2. Asterisks indicated
statistical significance (* ≤ 0.05, ** ≤ 0.01; additional borderline significance: p = 0.1745 for HOXA5, p = 0.1745 for HOXA9 and P = 0.1172
for HOXA10).
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markedly differed among AML samples (Figure 5B). In
contrast to normal cells, the expression of Modifier 2 and
3 genes appeared to mirror the differences in HOX mRNA
levels. In general, HOXB expression was positively cor-
related with Modifier 2 genes (e.g., H3K27 demethylases;
R = 0.874). The correlation of HOXA gene expression levels
with Modifiers 2 genes was less pronounced (R = 0.506) in
all cases with the exception of the AML M3 subgroup. For
the Modifier 3 genes (e.g., DNMTs), there was a substantial
negative correlation with HOXB expression (R = −0.442;
Figure 6). However, in contrast to normal hematopoiesis,the observed inverse correlation between Modifier 2 and 3
genes was much less pronounced (except for AML M3 and
M4; R = −0.178; Figure 6).
For individual genes in the leukemic samples (Additional
file 9: Figure S8), there were several notable correlations.
For instance, the expression of JMJD3 with HOXB4 and
HOXB6 was strongly positively correlated (p = 0.0003
and 0.0012, respectively), while negatively correlated
with DNMT3b (p = 0.03). There was also strong correl-
ation on a one-to-one basis between genes in the HOXA
cluster and for genes in the HOXB cluster. However, in
contrast with the healthy samples, there was only a weak
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ent HOX clusters.
Discussion
Several reports have demonstrated that HOX genes are
not only potent regulators of embryonic development but
also play significant roles in the regulation of many
processes in adult organisms, including hematopoiesis
[37-39]. The overall role of HOX clusters in addition to
that of particular HOX genes in hematopoiesis have
been revealed by various knock-out and overexpression
studies of human hematopoietic cells or by studies usingmouse models [40-43]. However, the degree to which
HOX genes contribute to the process of leukemogenesis
has not yet been elucidated.
The aberrant expression of HOX genes has been re-
ported in the majority of leukemia patients. However, it
remains unknown whether this aberrant expression repre-
sents a genuine driver of leukemogenesis or a passenger
effect reflecting a differentiation block. Another possible
explanation takes into consideration an impact of the mo-
lecular aberrations present in leukemic cells with further
biological consequences. Here, we attempted to shed light
on the expression of HOX genes in normal hematopoietic
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Figure 4 HOX gene expression patterns in corresponding differentiation stages of normal and malignat hematopoiesis. Comparison of
HOX gene expression patterns between AML M3 and sorted subpopulation of healthy BM cells (ID = G2).
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respect to their differentiation stage arrest in AML.
The crucial prerequisite for such an analysis is the ap-
propriate identification of subpopulations of healthy BM
cells representing the stages of myelopoiesis that can be
matched to their respective morphological counterparts
in AML. We managed to sort these subpopulations and
analyzed their HOX gene expression patterns. The expres-
sion of HOX genes was higher at the initial stages of he-
matopoiesis and gradually decreased with the maturation
of the hematopoietic cells, supporting the generally ac-
cepted hypothesis that HOX genes are strong regulators of
hematopoiesis (particularly at the early stages) [37].
A comparison of matched normal and malignant
hematopoietic precursor cells at the same differentiation
stage demonstrated the distinct expression patterns of
the HOX genes in the leukemic cells. This indicates that
the aberrant patterns of HOX gene expression cannot be
simply explained by the differentiation statuses at which
the cells have been arrested. This is similar to what we
previously observed in pediatric patients with ALL, who
were found to exhibit differential HOX gene expres-
sion between the subgroups and their matched nor-
mal precursors according to differentiation stage [15].
Altogether, our results support the hypothesis that the
dysregulation of HOX genes is involved in the process
of neoplastic transformation.
The analysis of childhood AML patients revealed a dif-
ferent expression profile of HOX genes among the FAB
subtypes and the subgroups of patients bearing unique
molecular rearrangements. The most diverse subgroup
of AML was AML M3, which showed the lowest levels
of HOX gene expression. This subgroup is characterized
by the presence of the PML-RARa fusion gene, which
generates an aberrant retinoic acid receptor unresponsiveto the physiological levels of this molecule. RUNX1-
RUNX1T1+, CBFb-MYH11+ and MLL-rearranged AML
patients also showed unique HOX gene expression pat-
terns. MLL rearrangements have been previously shown
to have a determinant role on HOX gene expression
[44]. Moreover, we revealed that AML patients bearing
the PML-RARa fusion gene had low expression levels of
the HOX genes regardless of FLT3/ITD status. This
finding is even more interesting considering that FLT3/
ITD has been shown to be associated with the upregu-
lated expression of HOX genes in leukemia patients [33].
Therefore, we performed an analysis of a larger cohort
of AML patients [34] from Erasmus MC-Sophia Chil-
dren’s Hospital and replicated the results drawn from
our cohort of pediatric AML patients. This analysis
showed that despite the overall upregulation of the
HOX genes in FLT3/ITD+ AML patients, HOX gene ex-
pression in FLT3/ITD+ PML-RARa+ patients was signifi-
cantly lower compared to the FLT3/ITD+ patients without
this fusion protein. Therefore, in this case, the PML-RARa
fusion gene may be superior to FLT3/ITD with respect to
its role in the process of malignant transformation.
Based on these results, we suggest that AML-specific
fusion oncoproteins may impact the upstream pathways
that deregulate the HOX genes, thereby acting as the
major underlying factors of their characteristic expres-
sion patterns observed in leukemic cells.
Our analysis of the AML patients also showed sig-
nificantly lower expression levels of HOXA in the SR
compared with the HR patients (in accordance with a
previous study [14]). These results suggest that the as-
sessment of HOX gene expression patterns may allow
for the prediction of aggressive cases of leukemia and
may therefore be taken into consideration in risk stratifi-
cation. However, we suggest that this observation is a
AML patients –morphological subgroups
Healthy BM –stages of myeloid differentiation
A
B
Figure 5 Expression patterns of chromatin modifiers and HOX genes in subpopulations of healthy BM and AML cells. A. Subpopulations
of healthy BM; B. AML patient subgroups. Lines connect values between categories (e.g., differentiation stages) to visually enhance depiction of
trend across subgroups.
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molecular aberrations to particular AML risk groups
(i.e., PML-RARa+ patients with the lowest HOXA gene ex-
pression levels being assigned to the SR group and
MLL+ cases with the highest expression levels of HOXA
genes being allocated to the HR group) and not an in-
dependent prognostic factor.
Considering the profound contribution of chromatin
modifiers to the embryonic regulation of HOX genes
and the essential roles of HOX genes in hematopoiesis,
the dysregulation of chromatin modifiers may deregulate
the entire process of hematopoiesis and subsequently
lead to malignant transformation. However, the exact
roles of epigenetic modifications in the regulation of
leukemic HOX gene expression remain to be elucidated.
It has recently been shown that HOX genes possess
unique chromatin regions called bivalent domains. Thesedomains are characterized by the presence of both repres-
sive (methylated H3K27) and activating (methylated
H3K4) histone methylation marks and are found in genes
poised to be activated according to cell-specific require-
ments [45]. To determine the role of chromatin modifiers
in the regulation of HOX genes in normal hemato-
poiesis and leukemogenesis, we analyzed the expression
patterns of DNA methyltransferases, histone H3K27/
H3K4 demethylases, and selected PcG and TrxG genes
in subpopulations of healthy BM cells and BM samples
of patients with AML. We found an inverse correla-
tion of histone demethylase (Modifiers 2) and DNMT
(Modifiers 3) gene expression in normal and malignant
hematopoiesis. In contrast to healthy hematopoiesis, we
found an interesting correlation between chromatin
modifier gene expression and that of the HOX genes in
the AML samples. The most pronounced correlation
Figure 6 Relationship of expression patterns of chromatin modifiers and HOX genes in subpopulations of healthy BM and AML cells.
Lines connect values between categories (e.g., differentiation stages) to visually enhance depiction of trend across subgroups.
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relationship of the HOX genes with the epigenetic mod-
ifiers in this morphological subgroup could be affected
by the presence of the PML-RARa fusion gene. In par-
ticular, HOX gene expression was positively associated
with the histone H3K27 demethylases, JMJD3 and UTX,
and inversely correlated with DNMT3b. Notably, both
JMJD3 and UTX have recently been suggested to play
roles in hematopoiesis [24,46]. Moreover, UTX has been
shown to directly bind to the HOXB1 locus [21,24]. Taken
together, the results implicate chromatin modifiers in the
establishment of the aberrant leukemic expression of
HOX genes in pediatric AML patients.
Although the expression of BMI1 was not altered during
hematopoiesis, a Spearman correlation analysis showed
that this gene was positively correlated with HOX gene
expression in the leukemic samples. It has been re-
ported that BMI1 determines the proliferating abilities
of the cells by inhibiting the p16 gene. HOXA9 was also
shown to target p16 and impair the senescence of cells
[47]. Thus, the expression levels of the histone methyl-
transferase BMI1 are likely to reflect the proliferation
statuses of leukemic cells without directly impacting
HOX gene expression [48].
Interestingly, the PML-RARa and RUNX1-RUNX1T1
fusion oncogenes have been shown to cooperate with re-
pressive complexes, leading to alterations in chromatin
architecture. PML-RARa causes profound changes in the
epigenetic landscape, mainly by recruiting chromatin-modifying enzymes to target sequences or by the de-
regulation of their functions [49,50]. Furthermore, recent
studies have shown that the degradation of the PML-
RARa oncoprotein results in dramatic changes to the
landscape of histone modifications [51]. Similarly, RUNX1-
RUNX1T1 has also been shown to recruit epigenetic mo-
difiers to target sequences [52]. These findings together
with our data suggest that AML-specific oncoproteins
regulate HOX gene expression through epigenetic modi-
fications. However, further studies are needed to under-
stand the roles of epigenetic modifiers in the regulation
of normal as well as leukemic HOX gene expression and
their cooperation with AML fusion oncoproteins.
In summary, we found that the expression patterns of
the HOX genes in leukemic cells are not solely determined
by their particular differentiation stages. Conversely, we
assume that the specific molecular aberrations that are
typical of AML are the major determinants of the leuke-
mic expression patterns of the HOX genes. Our results
also demonstrate the differing contributions of epigenetic
modifiers to HOX gene expression in healthy and malig-
nant hematopoiesis.Additional files
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